Los Angeles Capital Management LLC Buys Shares of 20,196 Annexon, Inc. $ANNX

Los Angeles Capital Management LLC bought a new stake in Annexon, Inc. (NASDAQ:ANNX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,196 shares of the company’s stock, valued at approximately $48,000.

A number of other hedge funds have also made changes to their positions in the stock. Mutual of America Capital Management LLC boosted its holdings in shares of Annexon by 4.7% during the second quarter. Mutual of America Capital Management LLC now owns 1,078,961 shares of the company’s stock worth $2,590,000 after purchasing an additional 48,278 shares during the period. CWM LLC increased its stake in Annexon by 212.9% in the 2nd quarter. CWM LLC now owns 17,734 shares of the company’s stock valued at $43,000 after buying an additional 12,066 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new position in Annexon in the 2nd quarter valued at approximately $29,000. Matauro LLC purchased a new stake in Annexon in the 2nd quarter worth approximately $27,000. Finally, J. Safra Sarasin Holding AG lifted its position in Annexon by 49.9% in the 2nd quarter. J. Safra Sarasin Holding AG now owns 381,441 shares of the company’s stock worth $915,000 after buying an additional 126,903 shares in the last quarter.

Annexon Stock Up 6.0%

Shares of ANNX opened at $3.20 on Wednesday. The firm has a market cap of $382.83 million, a price-to-earnings ratio of -2.48 and a beta of 1.28. The company’s fifty day moving average is $2.99 and its 200-day moving average is $2.54. Annexon, Inc. has a 12 month low of $1.28 and a 12 month high of $5.66.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, research analysts predict that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ANNX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, October 8th. Zacks Research raised Annexon from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Annexon in a research report on Friday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Annexon presently has an average rating of “Hold” and an average target price of $12.50.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.